Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR

World Journal of Surgery

Volumn 34, Issue 9, 2010, Pages 2083-2089

  Ito, Seiji ^a   Kodera, Yasuhiro ^b   Mochizuki, Yoshinari ^a   Kojima, Taiki ^a   Nakanishi, Hayao ^a   Yamamura, Yoshitaka ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CARCINOEMBRYONIC ANTIGEN; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PERITONEUM LAVAGE; PERITONEUM TUMOR; PHASE 2 CLINICAL TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STOMACH TUMOR;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PERITONEAL LAVAGE; PERITONEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STOMACH NEOPLASMS; TEGAFUR;

EID: 79952112096     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0573-6     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Boku T, Nakane Y, Minoura T et al (1990) Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 77:436-439
3. Kodera Y, Nakanishi H, Yamamura Y et al (1998) Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 79:429-433
4. Ito S, Nakanishi H, Kodera Y et al (2005) Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer 93:986-992
5. Kodera Y, Nakanishi H, Ito S et al (2002) Quantitative detection of disseminated free cancer cells in peritoneal washes with realtime reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg 235:499-506
6. Nakanishi H, Kodera Y, Torii A et al (1997) Detection of carcinoembryonic antigen-expressing free tumor cells in peritoneal washes from patients with gastric carcinoma by polymerase chain reaction. Jpn J Cancer Res 88:687-692
7. Nakanishi H, Kodera Y, Yamamura Y et al (2000) Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. Int J Cancer 89:411-417
8. Chaudhuri TR, Mountz JM, Rogers BE et al (2001) Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. Gynecol Oncol 82:581-589
9. Kurebayashi J, Nukatsuka M, Fujioka A et al (1997) Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clin Cancer Res 3:653-659
10. Yokoyama H, Nakanishi H, Kodera Y et al (2006) Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent protein-tagged human gastric cancer cell line. Clin Cancer Res 12:361-368
11. Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441-1447
12. Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
13. Koizumi W, Kurihara M, Nakano S et al (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191-197
14. Sakata Y, Ohtsu A, Horikoshi N et al (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
15. Kinoshita T, Nashimoto A, Yamamura Y et al (2004) Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 7: 104-109
16. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
17. Nakanishi H, Kodera Y, Yamamura Y et al (1999) Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol 43(Suppl):S32-S36
18. Wolfrum F, Vogel I, Fandrich F et al (2005) Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 390:430-441
19. Mori K, Suzuki T, Uozaki H et al (2007) Detection of minimal gastric cancer cells in peritoneal washings by focused microarray analysis with multiple markers: clinical implications. Ann Surg Oncol 14:1694-1702
20. Fujita Y, Terashima M, Hoshino Y et al (2006) Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer. Gastric Cancer 9:308-314
21. Mimori K, Fukagawa T, Kosaka Y et al (2008) Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res 14:2609-2616
22. Kodera Y, Ito S, Mochizuki Y et al (2009) A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol 35:1158-1163
23. Dalal KM, Woo Y, Kelly K et al (2008) Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer 11:206-213
24. Kodera Y, Nakanishi H, Ito S et al (2006) Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of follow-up. J Am Coll Surg 202:231-236
25. Tsuburaya A, Sakamoto J, Morita S et al (2005) A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit). Trial Jpn J Clin Oncol 35:672-675
26. Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277-283
27. Kang Y, Chang H, Zang D et al (2008) Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: a randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322). J Clin Oncol 26(Suppl):abstr LBA4511
28. Kodera Y, Ito Y, Ito S et al (2007) Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 54:960-963
29. Ohashi N, Kodera Y, Nakanishi H et al (2005) Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 27:637-644